Background. Epidemiologic studies that evaluate the relationship between previous antibiotic use and acute gastroenteritis (AGE) in the pediatric population are currently lacking.
Worldwide, diarrheal diseases are a leading cause of pediatric morbidity and death; 1.5 billion episodes and 1.5 to 2.5 million deaths have been estimated to occur annually among children <5 years of age [1] . Among children <5 years of age in the United States, acute gastroenteritis (AGE) accounts for >1.5 million outpatient visits, 200 000 hospitalizations, approximately 300 deaths, and a cost to the US healthcare system of approximately $1 billion each year [1] . Most cases of pediatric AGE that have a known etiology can be attributed to viruses; norovirus and rotavirus are the most prevalent pathogens [2] .
There is evidence to suggest that the intestinal microbiota plays a role in protecting against norovirus infection. Antibiotic-treated mice infected with murine norovirus have serum antiviral immunoglobulin G levels that are lower 35 days after infection than those of microbially colonized mice [3, 4] . In addition, a higher abundance of lactobacilli as a result of probiotic-fermented milk ingestion correlates with quicker recovery from human norovirus-induced fever [4, 5] . A higher abundance of lactobacilli after experimental vitamin A treatment is correlated similarly with inhibition of murine norovirus infection [4, 6] .
In contrast, evidence indicates also that the intestinal microbiota can facilitate norovirus infection. Depletion of the intestinal microbiota via antibiotic administration in mice leads to reduced norovirus replication, decreased viral shedding, and failure to establish persistent infection [3, 4, 7, 8] . In addition, infection of B cells by human norovirus is facilitated by binding to histo-blood group antigen-expressing enteric bacteria [7] .
There is mixed evidence regarding potential risks or protective effects that intestinal microbiota might have with respect to rotavirus infections. Probiotics have been shown to reduce the duration of viral diarrhea, and the administration of Lactobacillus rhamnosus GG reduces rotavirus shedding [9] . Soluble factors from commensal bacteria have also been shown to block rotavirus infection in intestinal epithelial cells in vitro [10] . Meanwhile, another study found that antibiotic-treated mice infected with rotavirus have reduced levels of viral genomes in their intestinal tissues, delayed viral shedding, and reduced incidence and duration of diarrhea than do controls [11] . The same study also found that germ-free and antibiotic-treated mice have substantially higher antiviral antibody responses than microbially colonized controls [11] .
Although it is difficult to discern from these studies the overall role played by the intestinal microbiota in norovirus and rotavirus infection, evidence suggests that the microbiota is involved in some capacity. However, despite the biologic evidence that the intestinal microbiota is involved in norovirus and rotavirus infections, epidemiologic studies that evaluate the relationship between antibiotic use and AGE caused by these pathogens have been lacking. The primary goals of this study were to (1) evaluate previous antibiotic use as a risk factor for AGE among children, specifically that caused by norovirus or rotavirus, and (2) assess the association between previous antibiotic use and the severity of AGE among children.
METHODS

Surveillance System
Since 2006, the New Vaccine Surveillance Network (NVSN) has conducted active population-based surveillance for AGE in children. In this study, we performed a post hoc analysis using data from an NVSN site, the Vanderbilt University Medical Center, located in Nashville (Davidson County), Tennessee, between December 1, 2014, and November 30, 2015.
Inclusion/Exclusion Criteria
Children with AGE were enrolled if they were between the ages of 15 days and 17 years and were hospitalized or visited the emergency department (ED) or outpatient clinic at the Vanderbilt University Medical Center between December 1, 2014, and November 30, 2015, with diarrhea (≥3 episodes within 24 hours) or vomiting (≥1 episode within 24 hours), their illness duration was ≤10 days, and informed consent was obtained from their parent or guardian. Enrolled patients were screened for preexisting conditions and excluded from eligibility if they had a noninfectious cause of diarrhea, had a history of immunodeficiency, were enrolled previously for the same AGE episode, or were transferred from another hospital. Enrolled healthy controls were children between the ages of 15 days and 17 years who were frequency matched according to age group and timing of enrollment at scheduled well-child visits. Additional details on enrollment were published previously [12, 13] .
Specimen Testing and AGE Outcome Definitions
Whole stool specimens were obtained within 10 days of symptom onset from patients with AGE and within 5 days of visit from healthy controls. Norovirus testing was performed by the Tennessee Department of Health using real-time quantitative reverse transcription polymerase chain reaction (RT-PCR), and rotavirus testing was performed at the Vanderbilt University Medical Center using an enzyme-linked immunosorbent assay (EIA). Confirmatory testing with repeat EIA or PCR was performed at the Centers for Disease Control and Prevention on all site EIA-positive specimens. Four AGE outcome groups were defined for this study: overall AGE, norovirus-associated AGE, rotavirus-associated AGE, and nonnorovirus/nonrotavirus AGE. The overall AGE group represents patients with AGE who were enrolled in the study regardless of the pathogen detected; the norovirus-associated AGE group represents patients with AGE whose test results were positive for norovirus but negative for rotavirus; the rotavirus-associated AGE group represents patients with AGE whose test results were positive for rotavirus but negative for norovirus; and the nonnorovirus/nonrotavirus AGE group represents patients with AGE whose test results were negative for both norovirus and rotavirus. Patients whose test results were positive for both rotavirus and norovirus were not categorized into a separate outcome group but are represented in the overall AGE group. The control group was defined as children who were enrolled as healthy controls and whose specimen tested negative for both norovirus and rotavirus.
Demographic and clinical data were collected systematically through parent/guardian interviews at the time of enrollment. The primary exposure of interest, previous antibiotic use, was also obtained through parent interviews as a dichotomous variable indicating whether the child had received antibiotics by mouth, intravenously, or by injection in the 3 months before illness onset (or 3 months before enrollment for healthy controls). The time since last antibiotic dose (in days) was collected also for those who had reported antibiotic use in the 3 months before illness onset (or 3 months before enrollment for healthy controls).
Descriptive Analyses
All data analyses were conducted using SAS 9.4 (SAS Institute, Inc, Cary, North Carolina). A univariate analysis was performed to determine the distributions of age, sex, race, ethnicity, insurance type, clinical setting, and previous antibiotic use in the 4 defined AGE outcome groups (overall AGE, norovirus-associated AGE, rotavirus-associated AGE, and nonnorovirus/nonrotavirus AGE) and healthy controls. Bivariate analyses were conducted to examine the associations between potential confounding demographic and epidemiologic variables with overall AGE and previous antibiotic use. Potential confounding variables were identified for all AGE outcomes, but differences in potential models were negligible for the outcome of interest. For the sake of comparability, a single-model form (the overall AGE group) was selected. For additional details on model selection, see Supplementary Data.
Modeling Strategy
Multiple logistic regression was performed to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between antibiotic use in the 3 months before illness onset and outcome group. Multiple logistic regression was also performed using different cutoffs for days since last antibiotic dose before illness onset (≤3 weeks, >3 weeks, and unknown time frame) to further assess the temporal relationship between antibiotic use and the 4 defined AGE outcomes. These specific cutoffs for the timing of antibiotic use were chosen on the basis of the observed distribution to divide the data evenly into 3 groups.
An additional analysis in which norovirus-associated cases of AGE that had a cycle threshold (CT) of greater than 31 were excluded was performed. CT values, given by real-time quantitative RT-PCR, are inversely related to viral load; limiting the analysis to include patients with a lower CT value might make it more likely that the norovirus detected was the actual cause of the AGE symptoms, as opposed to the antibiotics themselves. A CT of 31 was used previously as a cutoff value for diagnosing norovirus-associated illness [14] .
To evaluate the potential association between AGE severity and previous antibiotic use, multiple logistic regression was performed using the patients' final level of care as the outcome. Two separate analyses were performed, one in which inpatient and outpatient visits were compared and the other in which ED and outpatient visits were compared. Outpatient visits were selected as the reference group for the analysis because they represent the least severe and largest number of cases.
The association between antibiotic use in the 3 months before illness onset and AGE severity was also assessed using modified Vesikari scores (MVSs), which were calculated from clinical information using a preestablished 20-point scoring system [15] . The MVS system is a type of clinical severity scale that has been validated to measure the severity of AGE in pediatric populations in the United States. MVSs were evaluated as a dichotomous variable using the median value for the overall AGE group as the cut point.
This study was approved by the institutional review boards at the Centers for Disease Control and Prevention and the Vanderbilt University Medical Center.
RESULTS
Univariate Analysis
A total of 1142 patients with AGE and 394 healthy controls were enrolled during the 1-year study period; 864 (76%) of the patients with AGE and 285 (72%) of the healthy controls provided a stool sample. Of the 864 patients with AGE who provided a stool sample, 213 (25%) were classified as having norovirus-associated AGE, 67 (8%) had rotavirus-associated AGE, 570 (66%) had nonnorovirus/nonrotavirus AGE, and 12 (1%) tested positive for both norovirus and rotavirus. Of the 285 healthy controls who provided a stool sample, 250 (88%) tested negative for both norovirus and rotavirus (Table 1) (Table 1) . The percentages of patients with reported antibiotic use in the 3 months before illness onset or enrollment were similar across the 4 AGE outcome groups (overall AGE, 21%; norovirus-associated AGE, 23%; rotavirus-associated AGE, 28%; and nonnorovirus/nonrotavirus AGE, 22%) and were higher than that reported among the healthy controls (9%).
Previous Antibiotic Use and Defined AGE Outcomes
After controlling for age, sex, and household income, we found that the odds of antibiotic use in the 3 months before illness onset was 2.6 (95% CI, 1.7-4.1) times higher for patients with AGE overall than for healthy controls ( For the association between antibiotic use ≤3 weeks before illness onset and overall AGE, we obtained an aOR of 4.6 (95% CI, 1.8-11.4). Similar aORs were obtained for norovirus-associated AGE, rotavirus-associated AGE, and nonnorovirus/nonnorovirus AGE (Table 2 ). For those who had reported antibiotic use >3 weeks before illness onset or an unknown time since illness onset, we obtained aORs of 1.7 (95% CI, 0.8-3.5) and 2.4 (95% CI, 1.2-4.7), respectively, in the overall AGE group. Similar aORs were obtained for the other AGE outcomes.
Previous Antibiotic Use and AGE Severity
The proportions of patients who used antibiotics in the 3 months before illness onset were higher among those who were inpatient (39.1%) and those who visited the ED (24.1%) than among those who were outpatient (13.3%) in the overall AGE group. For the overall AGE group, after controlling for age, sex, and household income, we found that the odds of antibiotic use in the 3 months before illness onset was 3.5 (95% CI, 1.8-7.1) times higher for those who were inpatient than for those who were outpatient. Comparing ED and outpatient cases, an aOR of 2.0 (95% CI, 1.4-2.9) was obtained for the overall AGE outcome.
The median MVS in the overall AGE group was 8 (interquartile range, 6-10) (Supplementary Table 3 ). Using multiple logistic regression, we found that among AGE cases overall, the odds of antibiotic use 3 months before illness onset was 2.1 (95% CI, 1.5-2.8) times higher for patients with an MVS of ≥8 than for those who had an MVS of <8.
DISCUSSION
The results of this study provide evidence that previous antibiotic use among children in Davidson County, Tennessee, was associated with increased odds of AGE, irrespective of etiology, and that this association was stronger for more recent antibiotic use. In addition, we found that antibiotic use in the 3 months before illness onset was associated with more severe AGE regardless of the specific etiology. These data suggest that the intestinal microbiota might play a role in overall protection against AGE among children, even AGE caused by a virus, because disruption of this microbiota through antibiotic use increases the odds of AGE.
The exact biologic mechanism by which the intestinal microbiota protects against AGE is not known, but the consistency of the association observed between previous antibiotic use and the 4 AGE outcomes considered in this study (overall AGE, norovirus-associated AGE, rotavirus-associated AGE, and nonnorovirus/nonrotavirus AGE) suggests a nonspecific protective mechanism. One possibility is that antibiotic use, which leads to disruption of the intestinal microbiota, causes reduced local antiviral antibody production. The intestinal microbiota has been shown to affect localized secretory immunoglobulin A production [16] .
The association between previous antibiotic use and AGE was stronger when antibiotics had been used within 3 weeks of illness onset than when used within 3 months. This finding is biologically plausible, given that antibiotics have the greatest effect on intestinal microbiota during the actual course of antibiotic administration, which typically lasts 7 to 10 days [17] . Antibiotics can also have long-term compositional effects on the intestinal microbiota. For example, Dethlefsen et al [18] found that a 5-day The ≤3-month time period included patients who used antibiotics for ≤3 weeks before illness onset. Percentages for subcategories (≤3 weeks, >3 weeks, or unknown time before illness onset) are based on the total number of patients in each AGE outcome group who had used antibiotics in the 3 months before illness onset.
course of ciprofloxacin led to complete microbial recovery in most cases by 4 weeks after exposure, but some compositional effects lasted for 6 months. These long-term compositional effects might be reflected by the observed association between antibiotic use and AGE, even 3 months before illness onset. The observed associations between previous antibiotic use and AGE were also robust to evaluations of the potential effects of antibiotic-associated diarrhea and reverse causality. Antibiotics are known to cause diarrhea directly in approximately 10% to 15% of patients [19] . This issue is exacerbated by the fact that detection of norovirus by RT-PCR can sometimes occur in asymptomatic individuals; thus, determining the cause of AGE symptoms in patients who had previous antibiotic use and evidence of norovirus infection can be difficult. This is less of a concern for rotavirus-associated cases of AGE because the EIA technique detects rotavirus at levels that are more likely to cause disease [20] . To address this potential problem, we performed an additional analysis that included only patients with norovirus-associated AGE and a CT of <31, which are indicative of a higher viral load. From this analysis, we obtained an aOR similar to that obtained for the association between antibiotic use in the 3 months before illness onset and norovirus-associated AGE, which indicates that previous antibiotic use is associated with norovirus-associated AGE. However, it is worth noting that the use of CTs is limited, because there is no clear well-defined cutoff value for disease-causing levels of norovirus [14] .
The potential for reverse causality, by which people might have taken antibiotics in response to symptoms of AGE being experienced, also exists. We tried to address this possibility by excluding patients who had reported antibiotic use less than 1 or 2 weeks before illness onset and found that the association was reduced but persisted in the absence of these patients, which indicates that the overall association was not driven entirely by potential reverse causality (see Supplementary Data).
This study had a few limitations that should be considered. First, it is possible that the association between previous antibiotic use and AGE can be explained in part by residual confounding caused by some underlying health condition. For example, antibiotic use might be an indicator for people who are sick more frequently, potentially in part because of some unknown genetic or immunologic deficiency. Because this study was a post hoc analysis of NVSN surveillance aimed primarily at determining the incidence and etiology of AGE, the selection criteria for controls were not necessarily optimized for specifically assessing the association with previous antibiotic use. Second, laboratory testing data for Clostridium difficile was not available for this analysis. Antibiotic exposure is a known risk factor for C difficile infection. The potential inclusion of C difficile-infected patients might have led to an overestimation of the association between antibiotic exposure and AGE. However, given the relatively low incidence of symptomatic C difficile infection in pediatric populations and the fact that children with chronic illness (>10 days' duration) were excluded from the study, this potential confounding likely did not affect the observed associations significantly. Third, previous antibiotic use was reported by parents and thus might have been subject to recall bias. In addition, approximately 40% of those who reported antibiotic use in the 3 months before illness onset could not recall the number of days since the last dose, which limited our ability to draw conclusions on the effect of time since antibiotic use. Fourth, we lacked information on the class, dose, and duration of antibiotics used, which limited the specificity of our analysis and conclusions. Last, the patients with AGE captured by the surveillance system likely represent those who were on the more serious end of the illness spectrum, because their symptoms were serious enough to seek health care. This bias toward more severe cases of AGE limits the generalizability of the result to medically attended AGE and might not be applicable to milder cases of AGE in the community.
Future studies could consider the dose, type/class (narrow vs broad spectrum), and duration of antibiotic use and might increase the specificity of evidence behind the observed association between previous antibiotic use and AGE among children. Additional studies could use medical records to ascertain information on antibiotic use, because doing so would reduce the potential for recall bias and might lead to more complete information on when the antibiotics were taken in relation to illness onset. Our findings provide further justification for the judicious use of antibiotics, especially among children. Reducing the unnecessary use of antibiotics not only would help stem the rising tide of antibiotic-resistant bacteria but also might help reduce the burden of AGE among children.
